AdipoGen Life Sciences

anti-TRAIL-R2 (human), mAb (TR2.21)

CHF 460.00
In stock
AG-20B-0028-C100100 µgCHF 460.00
More Information
Product Details
Synonyms TRAIL Receptor 2; DR5; KILLER; TNFRSF 10B; CD262
Product Type Monoclonal Antibody
Properties
Clone TR2.21
Isotype Mouse IgG1
Source/Host Purified from concentrated hybridoma tissue culture supernatant.
Immunogen/Antigen Recombinant human TRAIL-R2 (DR5).
Application

Flow Cytometry
Immunohistochemistry: (paraffin sections) (20μg/ml)
Optimal conditions must be determined individually for each application.

Crossreactivity Human
Specificity

Recognizes human TRAIL-R2. Does not cross-react with human TRAIL-R1, -R3 or -R4.

Purity ≥95% (SDS-PAGE)
Purity Detail Protein G-affinity purified.
Concentration 1mg/ml
Formulation Liquid. In PBS containing 10% glycerol and 0.02% sodium azide.
Isotype Negative Control

Mouse IgG1 Isotype Control

Other Product Data

Specially developed for the immunohistochemical detection of TRAIL-R2 in paraffin embedded tissue. Has been shown to detect TRAIL-R2 expressed at endogenous levels in paraffin-embedded tissue in different mammary carcinoma tissues. For IHC (paraffin sections) TRAIL-R2 specific staining protocol (see PDF on web).
UniProt link O14763: human TRAIL-R2

Shipping and Handling
Shipping BLUE ICE
Short Term Storage +4°C
Long Term Storage -20°C
Handling Advice After opening, prepare aliquots and store at -20°C.
Avoid freeze/thaw cycles.
Use/Stability Stable for at least 1 year after receipt when stored at -20°C.
Documents
Protocols Download PDF
MSDS Download PDF
Product Specification Sheet
Datasheet Download PDF
Description

TRAIL-R2 is a receptor for the cytotoxic ligand TRAIL. The adapter molecule FADD recruits caspase-8 to the activated receptor. The resulting death-inducing signaling complex (DISC) performs caspase-8 proteolytic activation which initiates the subsequent cascade of caspases (aspartate-specific cysteine proteases) mediating apoptosis. Promotes the activation of NF-κB.

Product References
  1. TRAIL/bortezomib cotreatment is potentially hepatotoxic but induces cancer-specific apoptosis within a therapeutic window: R. Koschny, et al.; Hepatol. 45, 649 (2007)
  2. Troglitazone-mediated sensitization to TRAILinduced apoptosis is regulated by proteasomedependent degradation of FLIP and ERK1/2- dependent phosphorylation of BAD: K. Grund, et al.; Cancer Biol. Ther. 7, 1982 (2008)
  3. Prognostic significance of tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) receptor expression in patients with breast cancer: T. M. Ganten, et al.; J. Mol. Med. 87, 995 (2009)
  4. Prognostic Value of Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL) and TRAIL Receptors in Renal Cell Cancer: S. Macher-Goeppinger, et al.; Clin. Cancer Res. 15, 650 (2009)
  5. Cytosolic and nuclear caspase-8 have opposite impact on survival after liver resection for hepatocellular carcinoma: R. Koschny, et al.; BMC Cancer 13, 532 (2013)
  6. Cancer cell-autonomous TRAIL-R signaling promotes KRAS-driven cancer progression, invasion, and metastasis: S. von Karstedt, et al.; Cancer Cell 27, 561 (2015)
  7. IAPs cause resistance to TRAIL-dependent apoptosis in follicular 1 thyroid cancer: T.A. Werner, et al.; Endocr. Relat. Cancer 17, 0479 (2018)
© 2017 Adipogen Life Sciences. Pictures: © 2012 Martin Oeggerli. All Rights Reserved.